טוען...
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
BACKGROUND: Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors. We present results of a pivotal clinical study H8Y-MC-HBBM assessing the efficacy of LY2140023 in improving symptoms as a monotherapy in pat...
שמור ב:
| הוצא לאור ב: | BMC Psychiatry |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4276262/ https://ncbi.nlm.nih.gov/pubmed/25539791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12888-014-0351-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|